<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35388182</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists.</ArticleTitle><Pagination><StartPage>3562</StartPage><MedlinePgn>3562</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41380-022-01545-3</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khani</LastName><ForeName>Elnaz</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6877-3366</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Entezari-Maleki</LastName><ForeName>Taher</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3653-3653</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. tentezari@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. tentezari@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>O4L1XPO44W</RegistryNumber><NameOfSubstance UI="D016666">Fluvoxamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017480">Receptors, sigma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Mol Psychiatry. 2022 Apr;27(4):1898-1907. doi: 10.1038/s41380-021-01432-3</RefSource><PMID Version="1">34997196</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mol Psychiatry. 2022 Sep;27(9):3563-3564. doi: 10.1038/s41380-022-01546-2</RefSource><PMID Version="1">35388183</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016666" MajorTopicYN="N">Fluvoxamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017480" MajorTopicYN="Y">Receptors, sigma</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000097605" MajorTopicYN="N">Sigma-1 Receptor</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>5</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35388182</ArticleId><ArticleId IdType="pmc">PMC8985056</ArticleId><ArticleId IdType="doi">10.1038/s41380-022-01545-3</ArticleId><ArticleId IdType="pii">10.1038/s41380-022-01545-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hashimoto Y, Suzuki T, Hashimoto K. Mechanisms of action of fluvoxamine for COVID-19: a historical review. Mol Psychiatry. 2022:1&#x2013;10. Online ahead of the print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8739627</ArticleId><ArticleId IdType="pubmed">34997196</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DA, Seki SM, Fern&#xe1;ndez-Casta&#xf1;eda A, Beiter RM, Eccles JD, Woodfolk JA, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019;11:eaau5266. doi: 10.1126/scitranslmed.aau5266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau5266</ArticleId><ArticleId IdType="pmc">PMC6936250</ArticleId><ArticleId IdType="pubmed">30728287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao JR, Chang KC, Chen CW, Wu SY, Su IJ, Hsu MC, et al. Endoplasmic reticulum stress triggers XBP-1-mediated up-regulation of an EBV oncoprotein in nasopharyngeal carcinoma. Cancer Res. 2009;69:4461&#x2013;67. doi: 10.1158/0008-5472.CAN-09-0277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-09-0277</ArticleId><ArticleId IdType="pubmed">19435892</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Farre B, Rovira J, Martinez D, Valera A, Garcia-Herrera A, Marcos MA, et al. In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications. Mod Pathol. 2014;27:1599&#x2013;611. doi: 10.1038/modpathol.2014.68.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/modpathol.2014.68</ArticleId><ArticleId IdType="pubmed">24762547</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens. 2021;10:763. doi: 10.3390/pathogens10060763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18:e1003773. doi: 10.1371/journal.pmed.1003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375:296&#x2013;301. doi: 10.1126/science.abj8222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj8222</ArticleId><ArticleId IdType="pubmed">35025605</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>